Boston, Massachusetts 02115


Purpose:

To examine pharmacoeconomics of IV acetaminophen (Ofirmev). Specifically, to examine its potential to improve hospital efficiency and patient outcomes. The investigators compare the addition of IV acetaminophen versus placebo on postoperative PACU recovery times, inpatient hospital length of stay (LOS), patient satisfaction scores, postoperative pain scores, consumption of opiates as rescue agents and side effects, and costs associated with postoperative medications among patients undergoing robotic-assisted laparoscopic prostatectomy (RALP).


Criteria:

Inclusion Criteria: - Patients undergoing robotic-assisted laparoscopic prostatectomy - ≥18 years old males - ASA class 1-4 Exclusion Criteria: - Chronic opiate use - Liver disease (known history of hepatitis B or C, cirrhosis, nonalcoholic steatohepatitis, history of alcoholism, ALT/AST greater than 3 times upper limit of normal in the past 3 months) - Allergy/hypersensitivity to acetaminophen - Patients with baseline dementia - Chronic diathesis - Chronic kidney disease


NCT ID:

NCT02369211


Primary Contact:

Principal Investigator
Richard Urman, MD
Brigham and Women's Hospital

Richard Urman, MD
Phone: 6177328222
Email: urmanr@gmail.com


Backup Contact:

N/A


Location Contact:

Boston, Massachusetts 02115
United States

Richard Urman, MD
Phone: 617-732-8222

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: November 21, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.